← Leaderboards
Michael G. Goggins
Johns Hopkins University
$19,822,981
Attributed
$19,822,981
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,822,981 · 9
By mechanism
U01$8,639,610 · 1
R01$6,616,415 · 3
P50$2,327,930 · 2
RC2$1,912,026 · 1
R03$327,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Scott E Kern$10,982,210
- Alison P Klein$15,423,583
- Gloria M. Petersen$29,119,396
- Ralph H Hruban$3,076,689
- Nicholas Jason Roberts$919,322
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of PancreasPancreasImageSamplingDiagnosticPancreatic NeoplasmPancreatic JuiceCancer EtiologyDetectionEarly DiagnosisCessation Of LifeMutationDiagnostic AccuracyHigh RiskScreeningLesionDiagnosisKras2 GeneClinical TrialsEvaluationBaseDisorder ControlLiquid Substance
Grant awards (46)
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study$706,934
U01 · FY2025 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study$671,593
U01 · FY2024 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$396,154
R01 · FY2024 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study$544,589
U01 · FY2023 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$408,666
R01 · FY2023 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance: a multi-center study$786,628
U01 · FY2022 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$408,665
R01 · FY2022 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$931,728
U01 · FY2021 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$417,006
R01 · FY2021 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$930,050
U01 · FY2020 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$417,006
R01 · FY2020 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$927,908
U01 · FY2019 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$954,328
U01 · FY2018 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$953,081
U01 · FY2017 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$416,661
R01 · FY2017 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$983,899
U01 · FY2016 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$416,661
R01 · FY2016 · CA · contact PI
Markers for Screening and Prognosis$285,911
P50 · FY2016 · CA · contact PI
Using markers to improve pancreatic cancer screening and surveillance$248,872
U01 · FY2016 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$416,661
R01 · FY2015 · CA · contact PI
Markers for Screening and Prognosis$307,822
P50 · FY2015 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$404,161
R01 · FY2014 · CA · contact PI
Markers for Screening and Prognosis$305,324
P50 · FY2014 · CA · contact PI
Using Markers to Improve Pancreatic Cancer Screening$416,716
R01 · FY2013 · CA · contact PI
Markers for Screening and Prognosis$303,700
P50 · FY2013 · CA · contact PI
Markers for Screening and Prognosis$324,812
P50 · FY2012 · CA · contact PI
Screening Markers for Persons with High Pancreatic Cancer Susceptibility$194,444
P50 · FY2011 · CA · contact PI
Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trial$962,168
RC2 · FY2010 · CA · contact PI
Markers of Early Pancreatic Cancer$282,659
R01 · FY2010 · CA · contact PI
Screening Markers for Persons with High Pancreatic Cancer Susceptibility$203,387
P50 · FY2010 · CA · contact PI
Predicting pancreatic cancer responses for a Parp inhibitor-based clinical trial$949,858
RC2 · FY2009 · CA · contact PI
Markers of Early Pancreatic Cancer$282,659
R01 · FY2009 · CA · contact PI
Screening Markers for Persons with High Pancreatic Cancer Susceptibility$202,198
P50 · FY2009 · CA · contact PI
Markers of Early Pancreatic Cancer$282,659
R01 · FY2008 · CA · contact PI
Screening Markers for Persons with High Pancreatic Cancer Susceptibility$200,332
P50 · FY2008 · CA · contact PI
Markers of Early Pancreatic Cancer$282,587
R01 · FY2007 · CA · contact PI
Markers of Early Pancreatic Cancer$286,606
R01 · FY2006 · CA · contact PI
CLASSIFYING PANCREATIC CANCERS BY METHYLATOR PHENOTYPES$265,431
R01 · FY2006 · CA · contact PI
CLASSIFYING PANCREATIC CANCERS BY METHYLATOR PHENOTYPES$271,819
R01 · FY2005 · CA
CLASSIFYING PANCREATIC CANCERS BY METHYLATOR PHENOTYPES$271,819
R01 · FY2004 · CA
CLASSIFYING PANCREATIC CANCERS BY METHYLATOR PHENOTYPES$271,819
R01 · FY2003 · CA
THE PanINs OF PANCREATITIS,PANCREAS CANCER AND CONTROLS$81,750
R03 · FY2002 · CA
FOLATE PATHWAY POLYMORPHISMS AND PANCREATIC CANCER RISK$81,750
R03 · FY2002 · CA
SCREENING MARKERS FOR HIGH PANCREATIC CANCER$0
P50 · FY2002 · CA
FOLATE PATHWAY POLYMORPHISMS AND PANCREATIC CANCER RISK$81,750
R03 · FY2001 · CA
THE PanINs OF PANCREATITIS,PANCREAS CANCER AND CONTROLS$81,750
R03 · FY2001 · CA